Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Children’s Cancer Group Multicentre Trial, JPLSG B-NHL-20)

Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Children’s Cancer Group Multicentre Trial, JPLSG B-NHL-20)

Introduction Children and adolescents with mature B cell non-Hodgkin lymphoma (B-NHL) are treated with short-intensive chemotherapy. The burden of short-term and long-term toxicity is highly relative to its high cure rate in good-risk patients. Although the addition of rituximab to standard lymphome...

Full description

Bibliographic Details
Main Authors: Hiroya Hashimoto, Masahiro Sekimizu, Tetsuya Mori, Naoto Fujita, Reiji Fukano, Yuhki Koga, Tetsuo Mitsui, Takeshi Mori, Daiki Hori, Makito Tanaka, Kentaro Ohki, Hideto Iwafuchi, Atsuko Nakazawa, Ryoji Kobayashi, Akiko M. Saito, Michi Kamei
Format: Article
Language:English
Published: BMJ Publishing Group 2024-03-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/3/e080762.full

Similar Items

Similar Items